Rhythm Pharmaceuticals Stock Performance
| RYTM Stock | USD 105.53 2.14 2.07% |
The company holds a Beta of 0.97, which implies possible diversification benefits within a given portfolio. Rhythm Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Rhythm Pharmaceuticals is expected to follow. At this point, Rhythm Pharmaceuticals has a negative expected return of -0.0421%. Please make sure to check Rhythm Pharmaceuticals' treynor ratio, as well as the relationship between the accumulation distribution and period momentum indicator , to decide if Rhythm Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Rhythm Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Rhythm Pharmaceuticals is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 60.4 M | |
| Total Cashflows From Investing Activities | -48.2 M |
Rhythm Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 11,181 in Rhythm Pharmaceuticals on October 30, 2025 and sell it today you would lose (628.00) from holding Rhythm Pharmaceuticals or give up 5.62% of portfolio value over 90 days. Rhythm Pharmaceuticals is currently does not generate positive expected returns and assumes 3.3313% risk (volatility on return distribution) over the 90 days horizon. In different words, 29% of stocks are less volatile than Rhythm, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Rhythm Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of Rhythm Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 105.53 | 90 days | 105.53 | about 51.79 |
Based on a normal probability distribution, the odds of Rhythm Pharmaceuticals to move above the current price in 90 days from now is about 51.79 (This Rhythm Pharmaceuticals probability density function shows the probability of Rhythm Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Rhythm Pharmaceuticals has a beta of 0.97 indicating Rhythm Pharmaceuticals market returns are highly reactive to returns on the market. As the market goes up or down, Rhythm Pharmaceuticals is expected to follow. Additionally Rhythm Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Rhythm Pharmaceuticals Price Density |
| Price |
Predictive Modules for Rhythm Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Rhythm Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Rhythm Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Rhythm Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Rhythm Pharmaceuticals is not an exception. The market had few large corrections towards the Rhythm Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Rhythm Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Rhythm Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.15 | |
β | Beta against Dow Jones | 0.97 | |
σ | Overall volatility | 5.34 | |
Ir | Information ratio | -0.05 |
Rhythm Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Rhythm Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Rhythm Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Rhythm Pharmaceuticals generated a negative expected return over the last 90 days | |
| Rhythm Pharmaceuticals has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 130.13 M. Net Loss for the year was (260.6 M) with profit before overhead, payroll, taxes, and interest of 155.86 M. | |
| Rhythm Pharmaceuticals currently holds about 235.6 M in cash with (113.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.64. | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from globenewswire.com: Johnson Fistel Begins Investigation on Behalf of Soleno Therapeutics, Inc. Shareholders Who Have Incurred Losses |
Rhythm Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Rhythm Stock often depends not only on the future outlook of the current and potential Rhythm Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Rhythm Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 61 M | |
| Cash And Short Term Investments | 320.6 M |
Rhythm Pharmaceuticals Fundamentals Growth
Rhythm Stock prices reflect investors' perceptions of the future prospects and financial health of Rhythm Pharmaceuticals, and Rhythm Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Rhythm Stock performance.
| Return On Equity | -0.86 | ||||
| Return On Asset | -0.27 | ||||
| Profit Margin | (1.10) % | ||||
| Operating Margin | (1.03) % | ||||
| Current Valuation | 6.6 B | ||||
| Shares Outstanding | 66.74 M | ||||
| Price To Book | 46.13 X | ||||
| Price To Sales | 39.41 X | ||||
| Revenue | 130.13 M | ||||
| EBITDA | (238.09 M) | ||||
| Cash And Equivalents | 235.6 M | ||||
| Cash Per Share | 4.64 X | ||||
| Total Debt | 3.94 M | ||||
| Debt To Equity | 0.01 % | ||||
| Book Value Per Share | 2.23 X | ||||
| Cash Flow From Operations | (113.88 M) | ||||
| Earnings Per Share | (3.10) X | ||||
| Total Asset | 392.27 M | ||||
| Retained Earnings | (1.16 B) | ||||
About Rhythm Pharmaceuticals Performance
By examining Rhythm Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Rhythm Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Rhythm Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. Rhythm Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 140 people.Things to note about Rhythm Pharmaceuticals performance evaluation
Checking the ongoing alerts about Rhythm Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Rhythm Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Rhythm Pharmaceuticals generated a negative expected return over the last 90 days | |
| Rhythm Pharmaceuticals has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 130.13 M. Net Loss for the year was (260.6 M) with profit before overhead, payroll, taxes, and interest of 155.86 M. | |
| Rhythm Pharmaceuticals currently holds about 235.6 M in cash with (113.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.64. | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from globenewswire.com: Johnson Fistel Begins Investigation on Behalf of Soleno Therapeutics, Inc. Shareholders Who Have Incurred Losses |
- Analyzing Rhythm Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Rhythm Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Rhythm Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Rhythm Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Rhythm Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Rhythm Pharmaceuticals' stock. These opinions can provide insight into Rhythm Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rhythm Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rhythm Pharmaceuticals. If investors know Rhythm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rhythm Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Rhythm Pharmaceuticals is measured differently than its book value, which is the value of Rhythm that is recorded on the company's balance sheet. Investors also form their own opinion of Rhythm Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rhythm Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rhythm Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rhythm Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rhythm Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rhythm Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rhythm Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.